COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of SYNTHETIC BLOOD INTERNATIONAL, INC.Oxygen Biotherapeutics, Inc. • September 22nd, 2008 • Services-commercial physical & biological research • California
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) CERTIFIES that, for value received, FIONA International S.A., (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or prior to (the “Terminatior Date”) but not thereafter, to subscribe for and purchase from Synthetic Blood International, Inc., a New Jersey corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant is $0.247. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein.
COMMON STOCK PURCHASE WARRANT To Purchase 500,000 Shares of Common Stock of SYNTHETIC BLOOD INTERNATIONAL, INC.Oxygen Biotherapeutics, Inc. • September 22nd, 2008 • Services-commercial physical & biological research • New Jersey
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) CERTIFIES that, for value received, VCU Intellectual Property Foundation (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or prior to May 22, 2013 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Synthetic Blood International, Inc., a New Jersey corporation (the “Company”), up to 500,000 shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $0.42. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 22nd, 2008 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research • Virginia
THIS AGREEMENT is made and entered into this 21st day of May, 2008, by and between: SYNTHETIC BLOOD INTERNATIONAL, INC. (hereinafter referred to as the “LICENSEE”) with its principal place of business at 3189 Airway Avenue Bldg. C, Costa Mesa, CA 92626, and VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (hereinafter referred to as the “LICENSOR”), and with its principal place of operation at Virginia Commonwealth University, 800 E. Leigh Street, Suite 113, Richmond, Virginia 23298-0568, United States of America.
CONSULTING AGREEMENTConsulting Agreement • September 22nd, 2008 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research
WHEREAS, the Company desires to engage the services of the Consultant to perform for the Company consulting services concerning matters relating to licensing Oxycyte to pharmaceutical companies as an independent contractor and not as an employee; and WHEREAS, the Consultant already has established contacts to pharmaceutical companies for the Company, and
